Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma

Purpose: Malignant peripheral nerve sheath tumors (MPNST) occur at increased frequency in individuals with neurofibromatosis type 1 (NF1), where they likely arise from benign plexiform neurofibroma precursors. While previous studies have used a variety of discovery approaches to discover genes associated with MPNST pathogenesis, it is currently unclear what molecular events are associated with the evolution of MPNST from plexiform neurofibroma. Experimental Design: Whole-exome sequencing was performed on biopsy materials representing plexiform neurofibroma (n = 3), MPNST, and metastasis from a single individual with NF1 over a 14-year period. Additional validation cases were used to assess candidate genes involved in malignant progression, while a murine MPNST model was used for functional analysis. Results: There was an increasing proportion of cells with a somatic NF1 gene mutation as the tumors progressed from benign to malignant, suggesting a clonal process in MPNST development. Copy number variations, including loss of one copy of the TP53 gene, were identified in the primary tumor and the metastatic lesion, but not in benign precursor lesions. A limited number of genes with nonsynonymous somatic mutations (βIII-spectrin and ZNF208) were discovered, several of which were validated in additional primary and metastatic MPNST samples. Finally, increased βIII-spectrin expression was observed in the majority of MPNSTs, and shRNA-mediated knockdown reduced murine MPNST growth in vivo. Conclusions: Collectively, the ability to track the molecular evolution of MPNST in a single individual with NF1 offers new insights into the sequence of genetic events important for disease pathogenesis and progression for future mechanistic study. Clin Cancer Res; 21(18); 4201–11. ©2015 AACR.

[1]  Seon-Yong Jeong,et al.  TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions , 2014, Oncology reports.

[2]  D. Gutmann,et al.  Neurofibromatosis type 1: a multidisciplinary approach to care , 2014, The Lancet Neurology.

[3]  Gang Chen,et al.  Mutant β-III Spectrin Causes mGluR1α Mislocalization and Functional Deficits in a Mouse Model of Spinocerebellar Ataxia Type 5 , 2014, The Journal of Neuroscience.

[4]  R. Lothe,et al.  Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis , 2014, Neuro-oncology.

[5]  Beau R. Webber,et al.  Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. , 2014, The American journal of pathology.

[6]  H. Gogas,et al.  Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. , 2014, Cancer letters.

[7]  D. Gutmann,et al.  BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. , 2014, Neuro-oncology.

[8]  I. Petersen,et al.  Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms , 2014, Acta Neuropathologica.

[9]  Qi Zhao,et al.  Spectrin: Structure, function and disease , 2013, Science China Life Sciences.

[10]  D. Boldrin,et al.  Survivin Expression and Prognostic Significance in Pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST) , 2013, PloS one.

[11]  A. Lupo,et al.  KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions , 2013, Current genomics.

[12]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[13]  L. Johannes,et al.  βIII Spectrin Regulates the Structural Integrity and the Secretory Protein Transport of the Golgi Complex* , 2012, The Journal of Biological Chemistry.

[14]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[15]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[16]  S. Carroll,et al.  Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system , 2012, Brain Research Bulletin.

[17]  D. Cooper,et al.  Microarray‐based copy number analysis of neurofibromatosis type‐1 (NF1)‐associated malignant peripheral nerve sheath tumors reveals a role for Rho–GTPase pathway genes in NF1 tumorigenesis , 2012, Human mutation.

[18]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[19]  Ken Chen,et al.  SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..

[20]  T. de Ravel,et al.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors , 2011, Genes, chromosomes & cancer.

[21]  B. Scheithauer,et al.  Array-Based Comparative Genomic Hybridization Identifies CDK4 and FOXM1 Alterations as Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor , 2011, Clinical Cancer Research.

[22]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[23]  N. Warrington,et al.  Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. , 2010, Cancer research.

[24]  A. Rojiani,et al.  CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration. , 2010, International journal of clinical and experimental pathology.

[25]  Karlyne M. Reilly,et al.  Schweinfurthin A Selectively Inhibits Proliferation and Rho Signaling in Glioma and Neurofibromatosis Type 1 Tumor Cells in a NF1-GRD–Dependent Manner , 2010, Molecular Cancer Therapeutics.

[26]  M. Dutia,et al.  Loss of β-III Spectrin Leads to Purkinje Cell Dysfunction Recapitulating the Behavior and Neuropathology of Spinocerebellar Ataxia Type 5 in Humans , 2010, The Journal of Neuroscience.

[27]  T. Kiehl,et al.  Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings , 2010, Journal of Cancer Research and Clinical Oncology.

[28]  G. Page,et al.  Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene , 2009, EMBO molecular medicine.

[29]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[30]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[31]  S. Jhanwar,et al.  Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. , 2009, Anticancer research.

[32]  R. Lothe,et al.  Germline and somatic NF1 mutations in sporadic and NF1‐associated malignant peripheral nerve sheath tumours , 2009, The Journal of pathology.

[33]  G. Hutchins,et al.  Nf1-Dependent Tumors Require a Microenvironment Containing Nf1 +/−- and c-kit-Dependent Bone Marrow , 2008, Cell.

[34]  N. Thomas,et al.  Germline and somatic NF1 gene mutations in plexiform neurofibromas , 2008, Human mutation.

[35]  J. Dumanski,et al.  High-Resolution DNA Copy Number Profiling of Malignant Peripheral Nerve Sheath Tumors Using Targeted Microarray-Based Comparative Genomic Hybridization , 2008, Clinical Cancer Research.

[36]  A. Stemmer-Rachamimov,et al.  Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. , 2008, Cancer cell.

[37]  D. Burns,et al.  Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. , 2008, Cancer cell.

[38]  D. Evans,et al.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 , 2006, Journal of Medical Genetics.

[39]  R. Lothe,et al.  Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours , 2006, The Journal of pathology.

[40]  M. Watson,et al.  Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. , 2006, Cancer research.

[41]  D. Piwnica-Worms,et al.  CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.

[42]  F. Tamanoi,et al.  Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation , 2004, Glia.

[43]  I. Bièche,et al.  Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR , 2004, Molecular Cancer.

[44]  M. Watson,et al.  Gene Expression Profiling Reveals Unique Molecular Subtypes of Neurofibromatosis Type I‐associated and Sporadic Malignant Peripheral Nerve Sheath Tumors , 2004, Brain pathology.

[45]  D. Gutmann,et al.  Recent advances in neurofibromatosis type 1 , 2004, Current opinion in neurology.

[46]  K. Hoffmann,et al.  Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors , 2004, Acta Neuropathologica.

[47]  R. Lothe,et al.  Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Pierotti,et al.  p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  M. Watson,et al.  Differential NF1, p16, and EGFR Patterns by Interphase Cytogenetics (FISH) in Malignant Peripheral Nerve Sheath Tumor (MPNST) and Morphologically Similar Spindle Cell Neoplasms , 2002, Journal of neuropathology and experimental neurology.

[50]  D. Burns,et al.  Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment , 2002, Science.

[51]  J. Barrett,et al.  Chondrocyte phenotype and cell survival are regulated by culture conditions and by specific cytokines through the expression of Sox-9 transcription factor. , 2001, Rheumatology.

[52]  D. Gutmann,et al.  NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. , 2001, The American journal of pathology.

[53]  R. Lothe,et al.  Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors , 2001, Genes, chromosomes & cancer.

[54]  Karlyne M. Reilly,et al.  Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects , 2000, Nature Genetics.

[55]  S. Colman,et al.  Chromosome 17 loss‐of‐heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1 , 2000, Genes, chromosomes & cancer.

[56]  Karlyne M. Reilly,et al.  Mouse models of tumor development in neurofibromatosis type 1. , 1999, Science.

[57]  S. Velasco-Miguel,et al.  Mouse tumor model for neurofibromatosis type 1. , 1999, Science.

[58]  D. Louis,et al.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. , 1999, The American journal of pathology.

[59]  Yeang H. Ch'ng,et al.  A widely expressed betaIII spectrin associated with Golgi and cytoplasmic vesicles. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  S. Pulst,et al.  Neurofibromatosis 2 tumour suppressor schwannomin interacts with βII-spectrin , 1998, Nature Genetics.

[61]  P. Marynen,et al.  TP53 mutations are frequent in malignant NFI tumors , 1994, Genes, chromosomes & cancer.

[62]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[63]  National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. , 1988, Neurofibromatosis.